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Abstract
Background: CDC25B phosphatase is a cell cycle regulator that plays a critical role in checkpoint control. Up-
regulation of CDC25B expression has been documented in a variety of human cancers, however, the relationships
with the alteration of the molecular mechanisms that lead to oncogenesis still remain unclear. To address this issue
we have investigated, in model cell lines, the consequences of unscheduled and elevated CDC25B levels.
Results: We report that increased CDC25B expression leads to DNA damage in the absence of genotoxic
treatment. H2AX phosphorylation is detected in S-phase cells and requires active replication. We also report that
CDC25B expression impairs DNA replication and results in an increased recruitment of the CDC45 replication factor
onto chromatin. Finally, we observed chromosomal aberrations that are also enhanced upon CDC25B expression.
Conclusion: Overall, our results demonstrate that a moderate and unscheduled increase in CDC25B level, as
observed in a number of human tumours, is sufficient to overcome the S-phase checkpoint efficiency thus leading
to replicative stress and genomic instability.
Background
Members of the CDC25 phosphatase family (CDC25A,
B and C) regulate cell cycle transitions through depho-
sphorylation of their substrates the CDK-Cyclin com-
plexes. As ultimate targets of the DNA damage
activated pathway, they also play a critical role in the
fate of the cells in response to injury [1,2]. The currently
emerging picture suggests that all three CDC25 phos-
phatases probably act at various stages of the cell cycle
depending on the presence of the specific CDK/Cyclin
complexes. Thus, CDC25B has been proposed to partici-
pate in the control of S-phase entry since specific anti-
sense RNA is able to block HeLa cell replication [3] and
is involved in the initiation centrosome duplication cycle
in S-phase [4]. Conversely, CDC25A has been shown to
play an activating role during mitosis (for review [5]).
Elevated expression of CDC25B has been documented
in a growing list of human cancers [2] suggesting a
potential role in the alteration of molecular processes
leading to oncogenesis. The mechanisms by which the
CDC25B level becomes deregulated in tumours remains
unclear but it does not appear that the overexpression
results from gene amplification or rearrangement.
CDC25B expression can be regulated at the transcrip-
tional [6,7], translational and post-translational levels
[8,9]. During the cell cycle, CDC25B levels begin to
increase from mid-S-phase, they peak during the G2-M
transition and decrease in mitosis [3]. In contrast with
CDC25C, CDC25B was shown to be unstable with a 30-
minute half-life, its degradation being proteasome
dependent [8-10]. The timing of the transition between
each phase of the cell cycle must be strictly respected to
maintain genomic stability. As far as CDC25B is con-
cerned, its degradation by the proteasome pathway and/
or inactivation by cytoplasmic sequestration appears to
be essential to prevent activation of CDK-cyclin com-
plexes and to avoid checkpoint overcome.
Very little is known about the mechanisms by which
increased CDC25B expression contributes to the onco-
genesis process. It has been shown that overexpression
of CDC25B results in checkpoint bypasss and premature
entry into mitosis [11,12]. We also recently reported
that moderate CDC25B expression is sufficient to allow
bypass of a G2/M checkpoint activated by DNA damage,
thus resulting in increased sensitivity to genotoxics and
increased mutagenesis [11]. Accordingly, it has been
proposed that after DNA damage CDC25B
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events leading to checkpoint recovery and progression
in mitosis [14].
However, as mentioned above all three CDC25 phos-
phatases have been shown to be involved in the control
of CDK-cyclin activities at the G1-S transition and in S-
phase [15-17]. It is therefore tempting to speculate that
in addition to critically perturbing the G2-M checkpoint,
elevated and unscheduled levels of one of these phos-
phatases to an extent similar to that observed in human
tumours might also have deleterious effects on the other
key transitions.
In this study we have investigated cell cycle progres-
sion in response to unscheduled expression of CDC25B
and found dramatic effects during DNA replication lead-
ing to replicative stress and genomic instability. These
results emphasize the relevance of the study of its
expression in human tumours and shed light on its
potential role in oncogenesis.
Results
CDC25B unscheduled expression and progression in S-
phase
To examine the impact of unscheduled CDC25B expres-
sion on cell cycle progression during S-phase we used a
U2OS cell line conditionally expressing an Ha epitope-
tagged CDC25B protein under the control of the tetra-
cycline promoter [18]. We first examined cell cycle pro-
gression after synchronization by a double thymidine
block and release in cells expressing Ha-CDC25B or
not. Cell cycle distribution was determined by flow cyto-
metry analyses and is shown in figure 1A as the percen-
tage of cells in S and G2-M phase. Progression in the
cell cycle appeared similar in both populations with a
peak of S-phase cells at 6-7 hours. However, we noticed
that an elevated level of CDC25B-expressing cells was
already in S-phase immediately after thymidine block
release and/or showed uncompleted DNA replication
while a majority initiated the G2 phase. Similar observa-
tions were also made in cells expressing CDC25B that
had been synchronized by nocodazole treatment and
mitotic shake off and release with 23% of BrdU incor-
poration in U2OS-CDC25B cells versus 17% in U2OS
cells, (Figure 1B). These observations could reflect pre-
mature entry into S-phase with subsequent perturbation
of entry into mitosis as suggested by the flow cytometry
analysis.
We thus examined the duration of S-phase in cells
expressing Ha-CDC25B or not. These cells were BrdU
labeled then chased with thymidine and collected at var-
ious times for flow cytometry analysis of BrdU positivity.
Nocodazole treatment was used during the experiment
to stop progression into mitosis. As shown in figure S1,
Additional file 1, BrdU positivity was increased at the
Figure 1 Overexpression of CDC25B alters progression in S-
phase but not replication duration. (A) U2OS cells conditionally
expressing Ha-CDC25B were synchronized by double thymidine
block (Materials and Methods). At the indicated time after release,
Ha-CDC25B induced cells (U2OS CDC25B) or not (U2OS) were
harvested and the cell cycle distribution was monitored by flow
cytometry after propidium iodide staining (PI). A western blot
analysis with monoclonal anti-Ha antibodies shows the Ha-CDC25B
level in the induced U2OS CDC25B cells. (B) U2OS cells conditionally
expressing Ha-CDC25B were synchronized in mitosis by nocodazole
treatment (100 nM, 17 h). Mitotic cells were recovered by shake off
at 0 h and grown in drug free medium. Expression of CDC25B was
achieved by tetracycline removal at the time of release (0 h). At
indicated times after CDC25B induction, cells were labeled with
BrdU (30 μM, 15 min) and the percentage of BrdU positive cells was
determined by flow cytometry analysis.
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Page 2 of 12beginning of the U2OS-CDC25B S phase, however over
time S-phase appeared identical in both cell populations
indicating that S-phase duration was similar. Together
with previous reports [16], these results suggest that
unscheduled CDC25B expression results in a premature
entry into S phase without impact on the duration of
DNA replication but with possible consequences on its
regulation and on its fidelity.
Elevated CDC25B expression in S-phase induces DNA
damage
We next examined the possible consequences of
unscheduled CDC25B expression on the occurrence of
replication-linked DNA damage. With this aim, we used
immunofluorescence microscopy to monitor g-H2AX
staining, a sensitive and early marker of DNA injury. As
shown in figure 2A (left panel) the U2OS cells expressing
Ha-CDC25B displayed a strong positive g-H2AX staining.
This positivity was also observed by western blot on total
extract of cells in S-phase after synchronisation by noco-
dazole block and release, but was never observed in
U2OS cells that do not express CDC25B (Figure 2A right
panel). To examine the relationship between S-phase and
the occurrence of DNA damage, we performed immuno-
fluorescence after double staining with g-H2AX and
BrdU of U2OS cells expressing CDC25B or not. As
reported in figure 2B, g-H2AX staining was found to be
largely associated with BrdU incorporating cells. Flow
cytometry analysis of cell cycle distribution confirmed
that while the overall percentage of cells displaying a g-
H2AX positivity was about 8% (Figure 2C, left panel),
most of the U2OS-CDC25B cells displaying DNA
damage were in S-phase with nearly 60% of g-H2AX
labeling in that phase of the cell cycle (right panel, Figure
2C). In contrast a very low staining level was observed in
U2OS cells as shown in the scatter plots.
In order to confirm this observation in a cellular con-
text in which the unscheduled expression of CDC25B is
limited to a level frequently observed in many tumour
cell lines, we made use of HCT116 cells that were engi-
neered to stably express a moderate level of Ha-
CDC25B. As shown in Figure 2D this expression is lim-
ited to about two-fold in HCT116 CDC25B+ (central
panel) while in contrast a much higher expression level
is achieved in U2OS cells. HCT116 and HCT116
CDC25B+ were synchronised by thymidine block and
processed to immunofluorescence detection after 3 h of
release. A g-H2AX staining was observed in most of the
HCT116 cells expressing Ha-CDC25B while a negligible
signal was observed in the parental cell line. This obser-
vation was confirmed by the quantification of the g-
H2AX fluorescence as shown in the right panel of the
figure 2D.
These observations were specific for CDC25B, as they
were not observed in U2OS cells conditionally
expressing CDC25C (see Figure S2, Additional file 2).
Thus, our results suggest a specific role for unscheduled
expression of CDC25B in the induction of DNA damage
during S-phase.
Replication is required for g-H2AX labeling in cells
expressing elevated levels of CDC25B
As 60% of the cells displaying g-H2AX staining were in
S phase, we explored whether active DNA replication
was necessary to observe DNA damage upon unsched-
uled expression of CDC25B. Asynchronous U2OS cells
were induced to express Ha-CDC25B and treated at the
same time with the DNA polymerase inhibitor aphidico-
lin to inhibit replication while increasing CDC25B
expression. After 20 hours the drug was removed to
resume cell cycle and the levels of g-H2AX and BrdU
incorporation were monitored by flow cytometry at each
indicated time after induction of CDC25B expression.
A ss h o w ni nf i g u r e3 A ,a tt h et i m eo fr e l e a s ef r o mt h e
aphidicolin block, cells were mainly arrested in G1 with-
out BrdU incorporation and did not present any g-
H2AX positivity. By contrast, when the cell cycle was
resumed by aphidicolin removal, progressive phosphory-
lation of g-H2AX was clearly detected in U2OS-
CDC25B by immunofluorescence staining and flow
cytometry 3 and 6 hours after release, and paralleled
BrdU incorporation. This positivity was not observed in
the control U2OS cells population that did not
expressed CDC25B. Moreover as shown in figure 3B,
treatment with the CDK inhibitor roscovitin (10 μM) at
the time of induction of CDC25B expression, resulted
after 17 h in only 3% of g-H2AX positivity while 11% of
g-H2AX positivity was observed when the cells were
treated 4 h hours after the induction of CDC25B expres-
sion. These data suggest a correlation between the ele-
vated level of CDC25B and its consequence on CDK2
activity, replication unwinding and g-H2AX labeling.
DNA damage was obvious as early as 3 hours after
aphidicolin block release and g-H2AX positivity was not
found to be associated with condensed, fragmented or
micronucleated morphology, indicating that the DNA
damage observed could not result from CDC25B-depen-
dent mitotic catastrophe and subsequent apoptosis (see
also figure S3A, Additional file 3).
Furthermore, when U2OS cells were synchronized in
mitosis and released in Ha-CDC25B induction condi-
tions, g-H2AX labeling was detected only 13 h after syn-
chronization when the cells entered S-phase, while Ha-
CDC25B positive cells were already detected 6 hours
before. Thus, despite expression of CDC25B during G1-
phase, DNA damage occurred only during DNA replica-
tion and long before entry into mitosis (Figure S3B,
Additional file 3).
Overall, these results indicate that DNA replication is
required to observe g-H2AX labeling upon unscheduled
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Page 3 of 12Figure 2 Elevated expression of CDC25B in S-phase induces g-H2AX labeling. (A) Asynchronous U2OS cells overexpressing Ha-CDC25B
(U2OS CDC25B) (or not) were subjected to immunofluorescence analysis after staining with anti-Ha and anti-g-H2AX antibodies (bar = 10 μM). In
the upper right part of A, a western blot analysis of Ha-CDC25B and endogenous CDC25B levels using anti-CDC25B antibodies. In the lower
panel, after synchronization by nocodazole treatment and mitotic shake off followed (-tet) or not (+tet) by CDC25B induction as described in
figure 1B, the cells were processed for western blot using antibodies against g-H2AX and Ha tag (bar = 10 μM). (B) Asynchronous U2OS cells
expressing Ha-CDC25B (U2OS CDC25B) or not (U2OS) were subjected to BrdU labeling for 15 min (30 μM), then processed for
immunofluorescence analysis using antibodies against g-H2AX and BrdU. (bar = 10 μM). (C) Asynchronous U2OS cells expressing Ha-CDC25B
were processed for flow cytometry analysis with g-H2AX antibodies and propidium iodide. The % indicates the quantification of g-H2AX labeling
in the global population (left panel) and in each phase of the cell cycle (right panel). Color code in flow cytometry: blue>red>green. (D) HCT116
and HCT116 CDC25B+ with a slightly elevated level of Ha-CDC25B were blocked by thymidine (2.5 mM) for 17 h then released in DMEM for 3 h.
The cells were processed for immunofluorescence using antibodies against g-H2AX and Ha-tag and for western blotting using antibodies against
CDC25B, Ha-tag, g-H2AX and actin as loading marker (bar = 10 μM). Frequency histogram from 2 immunofluorescence analyses, shows the
distribution of g-H2AX fluorescence intensity in the cells (t-test, parental HCT116 (black bars) compared to HCT116 CDC25B+ (red bars).
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damage is associated with replication stress and defects
in the initiation and/or progression of replication forks.
Elevated levels of CDC25B cause increased CDC45
recruitment on chromatin
It is well known that the initiation factor CDC45
requires the combined activation of the cyclin-depen-
dent kinase CDK and the Dbf4-dependent kinase DDK
to initiate replication firing of the inactive pre-replica-
tion complexes [19]. As CDK2-cyclinA is a bona-fide
substrate for CDC25B, the likely enhanced activation of
CDK2 by elevated levels of the phosphatase could result
in increased phosphorylation of CDC45 resulting in the
recruitment of this factor on the pre-replication com-
plexes. To test this hypothesis, we measured the amount
of CDC45 associated with the chromatin-bound fraction
after DNase treatment in U2OS cells expressing elevated
levels of CDC25B. The cells were harvested 3 h after
release from thymidine block to enrich in S-phase cells
and limit premature entry into mitosis due to CDC25B
overexpression [16]. As shown in Figure 4A, the ele-
vated and unscheduled expression of CDC25B resulted
in a significant increase of chromatin-associated CDC45,
whereas the CDC45 level recovered in the soluble frac-
tion was not significantly affected. Orc2 binding was not
modified by CDC25B level modulation and constitutes
an internal standard. As predicted this suggests also a
CDC25B involvement in the activation but not in the
licensing of replication. We next examined whether
DNA damage induced by unscheduled CDC25B expres-
sion was dependent on the activity of CDC45. With this
aim, CDC45 expression was invalidated in U2OS cells
expressing CDC25B by RNA interference and g-H2AX
was monitored by western blot. As depicted in figure
4B, DNA damage revealed by g-H2AX labeling was sig-
nificantly reduced in CDC45-depleted cells while no
changes were observed in untransfected cells or in cells
transfected with scrambled siRNA. Indeed, no DNA
damage was detected in U2OS cells that did not express
CDC25B.
These results strongly support the hypothesis that ele-
vated and unscheduled activity of CDC25B is responsi-
ble for abnormal CDK2-cyclin activation and the
subsequent phosphorylation of CDC45. This would
result in the deregulation of its recruitment on the repli-
cation complexes that could likely account for the
observed replication stress and the subsequent DNA
damage [20-22].
Elevated level of CDC25B impairs replication fork
progression
To gain insight into the mechanism by which unsched-
uled CDC25B expression could promote replication
stress we examined the progression of replication forks
in cells expressing or not CDC25B. With this aim, the
thymidine analogs CldU and IdU were successively
incorporated into DNA (see methods) and fluorescence
Figure 3 Replication is required for g-H2AX labeling in cells expressing elevated levels of CDC25B.( A )U 2 O Sc e l l sw e r ei n d u c e dt o
overexpress Ha-CDC25B by tetracycline removal for 20 hours together with aphidicoline (2 μg/ml). The cells were incubated with BrdU (30 μM)
for 15 min before harvesting at the indicated time (0, 3 h and 6 h) after release and staining with antibodies against g-H2AX for
immunofluorescence and rat BrdU and mouse g-H2AX together with propidium iodide for flow cytometry analysis (bar = 10 μM). The indicated
percentage corresponds to g-H2AX and BrdU positive cells. (B) The CDK inhibitor roscovitin (10 μM) was added at the time of CDC25B induction
in U2OS cells (0 h) or 4 h hours after the beginning of induction. A 17 h after CDC25B induction, flow cytometry was achieved after staining
with g-H2AX antibodies and propidium iodide. The indicated percentage corresponds to g-H2AX positive cells.
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Page 5 of 12microscopy was used to visualize, in each of the replica-
tion foci, the corresponding labeling detected with anti-
bodies to CldU (green) and IdU (red) (Figure 5). As
demonstrated by others [23], the DNA replication pro-
gression is inversely proportional to the colocalization of
the two markers, the larger the overlapping areas of the
CldU and IdU foci, the slower the fork migrates and
vice versa. This analysis was performed in U2OS cells
conditionally expressing CDC25B (Figure 5A) and in
HCT116 cells expressing CDC25B (Figure 5B) that were
synchronized by thymidine block and released for 2
hours to enrich the S-phase population. As shown, the
relative colocalization areas of CldU-IdU were signifi-
cantly more elevated in both cell types, indicating a sig-
nificant perturbation of the fork progression likely due
to fork stalling upon CDC25B expression.
To confirm that this observation in HCT116 CDC25B
+ cells was totally dependent on CDC25B expression,
we invalidated its expression by RNA interference using
siRNA against CDC25B that has already been validated
[11]. As presented in figure 5C, while scrambled siRNA
was inefficient, the reduction of CDC25B expression
with a specific siRNA led to a significant lowering of the
overlapping CldU-IdU areas reflecting an increase in
fork progression. These data demonstrate a clear rela-
tionship between unscheduled expression of CDC25B
and deregulation of fork progression. This replicative
stress is likely due to the abnormal CDC45 recruitment
on replication complexes.
Elevated levels of CDC25B cause chromosome instability
The ability of abnormal and unscheduled increased
levels of CDC25B to promote replication stress resulting
Figure 4 Elevated level of CDC25B causes increased CDC45 recruitment on chromatin. (A) U2OS cells conditionally expressing CDC25B
were induced (U2OS CDC25B) or not (U2OS) in the presence of 2.5 mM thymidine for 17 h then released from the cell cycle block by
thymidine removal. After 3 h, the cells were harvested and processed for western blot analysis of two chromatin extracts, the detergent-soluble
fraction (Sol. Chrm.) and the DNase1 soluble fraction (DNase). The CDC45 protein level was monitored using Orc2 as loading marker. A typical
western blot of one of the four independent experiments used for quantification is shown. * indicates a p value < 0.01 (t-test where U2OS
CDC25B is compared to U2OS). (B) U2OS conditionally expressing CDC25B were transfected with CDC45 or control siRNA (Scr) for 28 h or not
transfected (NT) then treated with 2.5 mM thymidine for 17 h in the absence of tetracycline to induce CDC25B expression. Cells were released
from thymidine block by thymidine removal from the media. After 3 h, total extracts were processed for western blot analysis using anti-Ha,
anti-CDC45, anti-g-H2AX and anti-actin antibodies as loading controls. The CDC45 antibody was already tested for its specificity in [46]. Non-
induced U2OS are shown as controls (U2OS).
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Page 6 of 12Figure 5 Elevated level of CDC25B causes perturbation of S-phase progression. (A) U2OS were induced to express Ha-CDC25B (U2OS
CDC25B) or not (U2OS) then incubated in the presence of 2.5 mM thymidine for 17 h and released. Two hours after release, replication sites
were pulse labeled for 30 min with CldU then for 30 min with IdU. After immunostaining with antibodies specific for CldU and IdU, the
overlapping foci areas were quantified in each isolated cell and the results were expressed as the colocalization ratio (about 50 cells were
analyzed). The insert shown in the central panel of this figure displays representative labeling with CldU and IdU and the typical merge figure
that supports colocalization quantification using Image J software. (B) HCT116 cells expressing (CDC25B+) or not (parental) elevated levels of
CDC25B (see figure 2) were processed after thymidine treatment as in (A). A total of 100 to 150 cells were analyzed. (C) HCT116 expressing
elevated levels of CDC25B (HCT CDC25B+) were transfected with a CDC25B siRNA (siCDC25B) or a control siRNA (siScr) for 24 h then treated as
in A and B. As controls, untransfected HCT116 CDC25B+ (NT) and parental cells (ctr). *** indicates a p value < 0.0001. A total of 130 to 170 cells
were analyzed.
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analyze this chromosome feature.
We examined chromosomal aberrations in metaphase
spreads that were prepared using U2OS cells expressing
CDC25B after colcemid treatment. The frequencies of
chromatid and chromosome aberrations such as gaps
and breaks were respectively 1.2% and 0.6% in U2OS
cells whereas they rose to 2.7% and 1.6% in U2OS cells
expressing CDC25B (Figure 6A). As illustrated in Figure
6B, a typical spreading of metaphase CDC25B-expres-
sing U20S cells revealed gaps, breaks and joined chro-
mosomes illustrating the chromosomal aberrations that
were detected.
Discussion
In this study, we show that a moderate and unscheduled
increase in CDC25B protein level, comparable to the
increased level that has been reported to be observed in
human tumours, has a critical incidence during S phase
through the generation of replication defects. We first
demonstrate that abnormal level of CDC25B expression
results in DNA damage essentially occurring in replicat-
ing cells. This observation is reminiscent of the prema-
ture activation of cyclin E- and cyclin A-dependent
kinase observed upon CDC25A overexpression [15]. It
also recalls the effect of ectopic expression of a constitu-
tively active CDK mutant that causes DNA damage spe-
cifically in S-phase. Furthermore, chemical inhibition of
CDK-cyclin can reverse the DNA damage observed in
conditional Chk1 knockdown ES cells [24]. Enhanced
activation of CDK2 by elevated levels of the phosphatase
CDC25B has already been shown [25,26], and overex-
pression of CDC25B was able to overcome the unrepli-
cated DNA checkpoint [16]. Chk1 therefore appears to
be critical in controlling initiation of replication and
elongation and probably acts through the modulation of
CDC25 phosphatase activity [21,22,27]. One likely
hypothesis to explain our observations would be that by
weakening the role of Chk1, elevated and unscheduled
expression of CDC25B in G1 phase would compromise
the checkpoint relative to the S phase and lead to
abnormal activation of CDK-cyclin activity associated to
DNA replication. This effect is consistent with Chk1
haplo-insufficiency observed in some Chk1 dependent
phenotypes with accumulation of DNA damage during
replication and failure to restrain mitotic entry [28,29].
CDK-cyclin complexes play an essential role in regulat-
ing the activity of replication factors such as Cdc6, Cdt1
and CDC45 (reviewed in [30]) as well as in chromatin
decondensation by phosphorylation of histone H1 to
gain access to DNA in S phase [31]. Here we report an
increased loading of the key replication factor CDC45
during S phase, upon elevated and unscheduled expres-
sion of CDC25B and a reversion of the DNA damage
that was correlated to the specific depletion of CDC45.
CDC45 is CDK-dependent for its activity on the chro-
matin and is required for origin unwinding and for the
loading of the replicative polymerases [19,32]. As bind-
ing of CDC45 to chromatin is rate limiting for DNA
replication, the CDC45 active form constitutes one of
the critical regulator for the activation of pre-replication
complexes [33] and increased loading of CDC45 in the
absence of CDC25 regulation by Chk1 has already been
correlated to replication stress [20-22]. Thus, an
increase of CDC25B expression albeit to a minor extent
close to physiological variations as observed in the
HCT116 CDC25B+ cells, could phenocopy a Chk1
depletion leading to inappropriate cell cycle transition,
Figure 6 Elevated level of CDC25B induces significant chromosomal aberrations. (A) U2OS were induced by tetracycline removal to
express Ha-CDC25B (CDC25B) or not (U2OS) during 24 h then chromosomal breaks, gaps and fusions were quantified on metaphase spreads. (B)
Representative metaphase spreads with breaks (arrow 1), gaps (arrow 2) and fusions (arrow 3).
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damage.
Although S-phase duration was not changed, we also
observed a decrease in the replication rate upon expres-
sion of CDC25B and we demonstrated that depletion of
its expression was sufficient to rescue a normal progres-
sion. As the replication rate is inversely correlated with
the density of active origins [34,35], an attractive expla-
nation for the occurrence of DNA damage in CDC25B
expressing cells would be the activation of unscheduled
and unstable replication origins [36,37]. Shortening the
inter origin distance induced by the formation of new
active origins could increase DNA torsion stress which
could in turn promote stalled and collapsed forks thus
leading to double strand breaks of DNA and a slow-
down of fork progression [38]. In contrast with other
oncogenes CDC25B deregulation leads to replicative
stress in the absence of detectable re-replication and
probably through the activation of new replication ori-
gins as already observed after Myc deregulation [39].
We also report an increase in numbers of chromoso-
mal aberrations such as gaps, breaks and joined chro-
mosomes that illustrates the deleterious consequences of
elevated CDC25B expression during S-phase and its
potential role in genomic instability. In line with this
observation, we previously reported that HCT116 cells,
expressing elevated levels of CDC25B, displayed an ele-
vated mutation rate compared to the parental cell line
[11]. CDC25A overexpression in primary human epithe-
lial cells was also previously shown to promote genomic
instability at common fragile sites, thus accounting for
the oncogenic consequences of its increased expression
in human tumours [40]. In the case of CDC25B, it has
been thought that as a regulator of the G2-M transition,
this phosphatase did not act at the G1-S transition and
in S-phase, and that the oncogenic properties associated
with its overexpression in tumours could be related to
G2-M checkpoint bypass and unscheduled entry into
mitosis. Our findings demonstrate that this vision was
incomplete. It appears that CDC25B expression must be
tightly controlled and particularly in S phase, any
unscheduled increase in its nuclear expression leading
to replication stress and checkpoint control deficiency.
Interestingly, CDC25B is mostly nuclear in G1 phase of
unperturbed HeLa cells and gradually moves to the
cytoplasm as cells progress to S phase depending on the
presence of Cyclin B1 [16] or on the p38 mitogen acti-
vated protein kinase activation suggesting a regulation
in response to various types of cellular stress [41]. Its
ability to be down regulated by p53 ([42] and personal
communication), well-known for its frequent inactiva-
tion in tumours, its in vitro transforming potential [43]
and its ability to promote unscheduled entry into S-
phase constitute essential features for the contribution
of CDC25B to oncogenesis according to the proposed
induced senescence model (for review [44]).
Conclusion
Our findings indicate that unscheduled and moderate
expression of CDC25B during S-phase is sufficient to
induce replicative stress and genomic instability. Since
abnormal expression of CDC25B has been found in
numerous cancers (reviewed in [2,45]) our results pro-
vide new insights into the molecular mechanisms of the
involvement of this phosphatase in tumorigenesis.
Methods
Cell culture and transfection
U2OS conditionally expressing Ha-CDC25B3 (B3 iso-
form) cells were grown as previously described [18].
Cells were synchronized and induced for CDC25B at
the G1-S transition by a double thymidine block as fol-
lows: 16 h of treatment with 2.5 mM thymidine and 5
μg/ml tetracycline to repress the promotor, then 16 h
release followed by the second thymidine block for 17 h
without tetracycline to induce CDC25B. Cells were syn-
chronized at the G2-M transition by nocodazole (100
nM, 17 h) with 5 μg/ml tetracycline then released, sha-
ken off to retrieve mitotic cells and induced for Ha-
CDC25B in the absence of tetracycline. HCT116 p53-/-
clones expressing elevated levels of CDC25B were gen-
erated and grown as previously described [11].
A previously validated siRNA for CDC25B with the
following sequence 5’AGACUGCAGAUACCCCUAU-3’
was used. Human CDC45 siRNA pool was purchased
from Santa Cruz (CA). Cells were electrotransfected
using AMAXA nucleofector following the manufac-
turer’s instructions for HCT116 and U2OS cells.
Immunofluorescence
Mouse anti-phospho Ser139 g-H2AX (clone JBW 301,
Upstate Biotechnology, Lake Placid, NY), rabbit anti-
phospho Ser139 g-H2AX (Upstate Biotechnology),
mouse anti-Ha tag (clone Ha.11 Covance), rabbit anti-
phospho H3-Ser210 (Upstate Biotechnology), rat anti-
BrdU (clone BU1/75 Serotec), mouse anti-BrdU (Becton
Dickinson), rabbit CDC25B antibody (C-20. Santa Cruz,
CA), mouse anti-actin (Chemicon, Temecula, CA), rab-
bit anti-CDC45 (ref. 20685. Santa Cruz). Mouse rabbit
and rat anti-IgG Alexa 488 and 594 for immunofluores-
cence (Molecular Probes, Invitrogen), rabbit and mouse
anti-HRP antibodies (Cell Signalling).
Cells cultured on glass coverslips were processed as
previously described then incubated with rabbit anti-g-
H2AX and mouse anti-Ha tag or rabbit anti-phospho
H3 Ser210 and mouse anti-phospho g-H2AX followed
by rabbit and mouse Alexa secondary antibody staining
[12]. Cells were mounted in Vectashield anti-fade
mounting medium and visualized using a DM6000
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ing, cells were incubated with 30 μM BrdU (Calbio-
chem) for 15 min and fixed with 3.7% formaldehyde for
10 min. The cells were processed as described in [23]
with some modifications: they were washed with PBS
and incubated with methanol for 5 min at -20°C then
treated with PBS/0.5%Triton ×100/0.02% SDS for 30
min at room temperature. DNA was denatured using
freshly prepared 1.5 M HCl, then neutralized by washing
with 0.1 M sodium borate (pH 8.5) and PBS. To block
non-specific binding, cells were incubated in 5%PBS-
BSA, 30 min to overnight at 4°C then submitted to anti-
g-H2AX or anti-BrdU for 1 h then two washes with PBS
followed by mouse anti-IgG Alexa 594 and rat anti-IgG
Alexa 488 respectively.
Replication focus detection with CldU and IdU was
performed on U2OS or HCT116 cells blocked by thymi-
dine (2.5 mM) for 17 h then released in DMEM for two
hours. Cells were incubated in medium containing 100
μM CldU (Sigma, St Quentin, France) for 30 min then
100 μM IdU for the last 30 minutes after washing with
hot medium. IdU incorporation was stopped with med-
ium containing thymidine (1 mM) then cells were fixed
with cold 70% ethanol. They were treated with 100%
methanol at -20°C for 5 min, washed twice with PBS
then incubated in 1.5 M HCl for 20 min. After two
washes with PBS, they were incubated in 0.5%
Tween20/0.25%BSA/5% fetal veal serum/PBS/(TBS) for
30 min in a humid box. Incubation in the primary anti-
body rat anti-BrdU against CldU and mouse anti-BrdU
against IdU in TBS for 2 hours was followed by anti-rat
IgG Alexa 594 and anti-mouse IgG Alexa 488 in TBS
respectively. Cells were washed twice in 0.5% Tween/
PBS then mounted in Vectashield solution and visua-
lized using a DM 6000 microscope. Pictures were
acquired with MetaMorph software, keeping the same
intensities for each fluorescent dye for all the pictures of
the same assay and the signals were measured using
ImageJ software. IdU-CldU colocalization was quantified
from the merge picture by dividing the colocalization
area by the total area for each nucleus and the non-
parametric Welch T corrected test was used to analyse
the data.
Flow cytometry
Cells were processed as previously described with mouse
anti-phospho Ser139 g-H2AX, followed by mouse anti-
IgG Alexa 488 [12]. DNA was stained with propidium
iodide (10 μg/ml) in the presence of RNase (5 μg/ml)
and analyses were done on a FACScan flow cytometer
(Cell Quest, Becton Dickinson, Mountain View, CA).
For BrdU incorporation assay, the cells were incubated
with 30 μM BrdU (Calbiochem) for 15 min, fixed as
above then DNA was denatured by freshly prepared 1.5
M HCl, then neutralized by 0.1 M sodium borate (pH
8.5) followed by PBS. After washing in 1%PBS-BSA, rat
anti-BrdU was added for 2 h together with mouse anti-
phospho g-H2AX then two PBS washes followed by rat
anti-IgG Alexa 488 and mouse anti-IgG Alexa 594
staining.
Chromatin fractionation and Western Blotting
U2OS cells were synchronized and induced for CDC25B
expression at the G1-S transition by a simple thymidine
block (2.5 mM, 17 h). After 3 h of thymidine release,
the cells were harvested and resuspended in buffer A
(10 mM HEPES pH 7.5, 1.5 mM MgCl2,1 0m MK C l ,
10% glycerol, 0.34 M sucrose, protease inhibitors (cock-
tail-Complete, Roche), 10 min on ice. EDTA 10 mM
was added for 30 min and this chromatin fraction
obtained after centrifugation (12 000 g, 3 min, 4°C)
represented the soluble fraction. The pellets were
washed twice in buffer A and incubated 30 min at RT
with 2000 U/ml DNaseI (Roche) and a further 30 min
at 4°C with 0.5 M NaCl. The DNase solubilized chroma-
tin fraction was obtained after centrifugation (12000 g, 3
min, 4°C).
Chromatin fractions and whole protein extracts were
electrophoresed on a 4%-12% SDS gradient gel (Invitro-
gen, Carlsbad, CA) and analysed by Western Blotting.
For protein quantification, pictures were acquired with a
Bioimaging Systems, Syngene Camera and the signals
measured using ImageJ software.
Metaphase chromosomes spreads
U2OS cells were induced for CDC25B or not for 24 hrs
at which point Colcemid (0.1 μg/mL; Gibco) was added
for the last 3 h to accumulate mitotic cells prior to tryp-
sinisation, centrifugation, resuspension in PBS, centrifu-
gation and swelling in hypotonic (50 mM) KCl solution
for 25 min at RT. A fixation solution of 100% ethanol/
acetic acid (3:1) was added and the cells were centri-
fuged, rinsed twice in ethanol/acetic acid before spread-
ing on slides and being left to dry. Chromosomes were
stained with 0.05 μg/ml DAPI/PBS (Sigma) for 10 min
then washed with several changes of PBS and mounted
with mounting medium (Dakocytomation) prior to
microscopy. About 30 spreads were scored for statistical
data.
Additional file 1: Analysis of S phase duration. Asynchronous cells
overexpressing CDC25B (U2OS CDC25B) or not (U20S) were treated with
nocodazole (200 nM) all along the assay. The cells were pulse labeled
with BrdU (30 μM, 15 min) then BrdU was replaced by thymidine (1
mM). The cells were collected at the indicated times and immunostained
with anti BrdU antibodies. The percentage of BrdU positive cells in S
phase was determined by flow cytometry analysis. 100% correspond to
the cell population before chase. As an example, the percentages of cells
in S phase at 0 h and 10 h after thymidine chase were measured as
shown in the two lower plots.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-29-
S1.PDF]
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Page 10 of 12Additional file 2: Analysis of g-H2AX staining in overexpressing
CDC25C U2OS cells. Asynchronous U2OS cells conditionally
overexpressing Ha-CDC25B or Ha-CDC25C by tertracycline removal (+)
[47] for 17 h were processed for flow cytometry analysis with g-H2AX
antibodies and propidium iodide. The results indicate the percentage of
g-H2AX positive cells in interphase (G1-S-G2) and mitosis.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-29-
S2.PDF]
Additional file 3: Analysis of g-H2AX staining during the cell cycle.
U2OS cells conditionally expressing Ha-CDC25B were synchronized in
mitosis by nocodazole treatment (100 nM, 17 h) as in figure 1B. At
indicated times after CDC25B induction, cells were processed for
immunofluorescence analysis using rabbit antibodies against g-H2AX
together with antibodies against phosphorylated histone H3 (panel A) or
with anti-Ha to detect CDC25B (panel B).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-29-
S3.PDF]
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